Vitalhub Corp. Reports Fourth Quarter and Full Year 2022 Results
Retrieved on:
Thursday, March 23, 2023
VHI, CAD, Financial statement, CDS, EBITDA, Acquisition, ARR, ADI, Cash flow, TSX, Growth, GBP, Bank, Health, Hand, Cryptocurrency, Video game, Pharmaceutical industry, Bookkeeping, Hicom
“The positive organic and accretive inorganic growth contributed to record Q4 and fiscal 2022 revenue, adjusted EBITDA(2), and annual recurring revenue (“ARR”)(1, 2).
Key Points:
- “The positive organic and accretive inorganic growth contributed to record Q4 and fiscal 2022 revenue, adjusted EBITDA(2), and annual recurring revenue (“ARR”)(1, 2).
- Gross profit as a percentage of revenue for Q4 2022 was 82% compared to 79% in Q4 2021 and 80% in Q3 2022.
- ARR (1, 2) grew by $5,177,935 to $36,145,150, achieving 17% growth in Q4 2022 versus Q3 2022.
- Cashflows from operations before changes in working capital was $7,119,817 for FY 2022 as compared to $1,972,933 for FY 2021.